HOME > Products and Technologies > Pipeline
ViroMed focuses on two areas - DNA/protein-based biopharmaceuticals and phytotherapeutics
Our major biopharmaceutical targets are cardiovascular, neurological and cancer
Category Technology Clinical trial BLA/NDA Market
Phase I Phase II Phase III
Biopharmaceuticals DNA VM202
Amyotrophic Lateral Sclerosis
(US Phase II Approved)
VM202
Diabetic Peripheral Neuropathy
(US Ongoing)
   
VM202
Coronary Artery Disease
(Korea Ongoing)
VM202
Peripheral Artery Disease
(US Ongoing)
   
VM206
Breast Cancer
(Korea Planned)
     
Protein     VM501
Chemotherapy- induced thrombocytopenia
(China Ongoing)
   
Botanical Drug       PG201
Osteoarthritis
(Korea launched)
Category Human trial Approval of Health claim Market
Nutraceuticals
(Korea)
    PG102
Hyper immune response
improvement


HX811
Joint Health improvement
HX106
Memory improvement